Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin

Sadzuka, Yasuyuki; Sugiyama, Ikumi; Tsuruda, Tomoko; Sonobe, Takashi

doi:10.1016/j.ijpharm.2005.12.043

Cited by 41 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FALT was demonstrated to be one of the physical factors that defined the pharmacokinetics of the PEG-modified liposomes. An increase in FALT with increase in PEG molecular weight led to enhancement in escape from reticuloendothelial system and augmentation in tumor uptake of liposomes (Sadzuka et al, 2002(Sadzuka et al, , 2006. Similar kind of results were observed, and the copolymer with PEG of molecular weight 5000 g showed higher FALT compared to micelles prepared with PEG of molecular weight 2000 g. A reduction in FALT was also seen with increase in the molecular weight of PCL block; these may be attributed due to decrease in PEG surface coverage (Riley et al, 1999).…”

Section: Discussionsupporting

confidence: 60%

Investigation on design of stable etoposide-loaded PEG-PCL micelles: effect of molecular weight of PEG-PCL diblock copolymer on thein vitroandin vivoperformance of micelles

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 60%

Investigation on design of stable etoposide-loaded PEG-PCL micelles: effect of molecular weight of PEG-PCL diblock copolymer on thein vitroandin vivoperformance of micelles

et al. 2012

View full text Add to dashboard Cite

show abstract

“…However, conventional liposomes do not undergo significant transport through the BBB in the absence of vector-mediated drug delivery (Misra et al 2003;Ishida et al 2006). Furthermore, these liposomes are coated with serum proteins immediately after intravenous administration and are rapidly removed from the bloodstream and cleared by the cells of the reticuloendothelial system (RES; Siwak et al 2002;Sadzuka et al 2006). The RES is a group of mononuclear cells originating from bone marrow that phagocytize small foreign particles in the vascular space (Lockman et al 2002).…”

Section: Systemic Drug Delivery Systemsmentioning

confidence: 99%

Biomaterials for the central nervous system

Zhong

Bellamkonda

2008

J. R. Soc. Interface.

215

163

View full text Add to dashboard Cite

Biomaterials are widely used to help treat neurological disorders and/or improve functional recovery in the central nervous system (CNS). This article reviews the application of biomaterials in (i) shunting systems for hydrocephalus, (ii) cortical neural prosthetics, (iii) drug delivery in the CNS, (iv) hydrogel scaffolds for CNS repair, and (v) neural stem cell encapsulation for neurotrauma. The biological and material requirements for the biomaterials in these applications are discussed. The difficulties that the biomaterials might face in each application and the possible solutions are also reviewed in this article.

show abstract

“…Many anthracycline liposomal formulations possess a singular PEG molecule that characterises the liposome. The new attempt to generate liposomes of anthracyclines with increased fixed aqueous layer thickness (FALT) by mixed (long and short chain) PEGylated liposomes (PEG2000-CHO and PEG2000-DSG) may improve the Anthracyclines as effective anticancer drugs anticancer effects better than a single-chain PEG-modified liposome (PEG2000-CHO) [83,84]. pH-sensitive liposomes with DOPE/HSPC/CHEMS/CHOL were also found to improve the liposomal drug release rate of anthracyclines, which is related to anticancer efficacy [85].…”

Section: Doxorubicinmentioning

confidence: 99%

Anthracyclines as effective anticancer drugs

Nadas¹,

Sun

2006

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Anthracyclines have received significant attention due to their effectiveness and extensive use as anticancer agents. At present, the clinical use of these drugs is offset by drug resistance in tumours and cardiotoxicity. Therefore, a relentless search for the 'better anthracycline' has been ongoing since the inception of these drugs > 30 years ago. This review focuses on the most recent pharmacology and medicinal chemistry developments on the design and use of anthracyclines. Based on their crystal structures as well as molecular modelling, a more detailed mechanism of topoisomerase poisoning by these new anthracyclines has emerged. Chemical modifications of anthracyclines have been found to possibly change the target selectivity among various topoisomerases and, thus, vary their anticancer activity. Additionally, recent sugar modifications of anthracyclines have also been found to overcome P-glycoprotein-mediated drug resistance in cancer therapy. The continued improvement of anthracycline clinical applications so far and the clinical trials of the 'third generation' of anthracyclines (such as sabarubicin) are also discussed. To finally find the 'better' anthracycline, further areas of research still need to be explored such as: the elucidation of the topoisomerase and P-glycoprotein crystal structures, molecular modelling based on crystal structure in order to design the next generation of better anthracycline drugs, the continued modifications of the anthracycline sugar moieties, and the further improvement of anthracycline drug delivery methods.

show abstract

Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin

Cited by 41 publications

References 18 publications

Investigation on design of stable etoposide-loaded PEG-PCL micelles: effect of molecular weight of PEG-PCL diblock copolymer on thein vitroandin vivoperformance of micelles

Investigation on design of stable etoposide-loaded PEG-PCL micelles: effect of molecular weight of PEG-PCL diblock copolymer on thein vitroandin vivoperformance of micelles

Biomaterials for the central nervous system

Anthracyclines as effective anticancer drugs

Contact Info

Product

Resources

About